Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISE

David Mott(Office Of Health Economics), Marco Pavesi, Roberto Bordonaro(Ospedale Garibaldi), Serena Hilman(Weston General Hospital), Arzu Betul Duran, Angus Robinson(Royal Sussex County Hospital), Josep Gumà, M. Mira Flores(Hospital Universitari Arnau de Vilanova), Bernard Rappe(Onze Lieve Vrouwziekenhuis Hospital), A. Pranzo(Astellas Pharma (United Kingdom)), L.-M. Dourthe, A. Serikoff(Honeywell (France)), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Marco De Santis(Agostino Gemelli University Polyclinic), S. Mallick(Hôpital Saint-Michel), Heather Payne(The Prostate Centre), Steven Joniau, B. Barón, Michael Herdman(National University of Singapore)
European Urology Open Science
July 1, 2020
10.1016/s2666-1683(20)33169-4
Cited by 0

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786